Undecimal Bio Launches with $18 Million to Expand siRNA Beyond the Liver
A new biotechnology startup named Undecimal Bio has officially launched with $18 million in funding. The company aims to push small interfering RNA technology beyond its traditional therapeutic boundaries in the liver and into new clinical areas.
The Next Phase for RNA Therapeutics
Small interfering RNA, commonly known as siRNA, has shown significant success in targeting conditions associated with the liver. However, delivering these genetic medicines to other parts of the human body has historically presented a major scientific challenge for researchers and drug developers.
Undecimal Bio was formed after Eleven Therapeutics spun out one portion of its operations earlier in the summer. With the newly secured $18 million in financial backing, the newly minted company plans to carve out the remaining operations and join other organizations attempting to broaden the delivery and application scope of siRNA technologies.
Future Directions and Challenges
While venture financing has allowed the startup to officially launch and begin its independent operations, translating early-stage delivery platforms into clinically proven treatments remains a complex hurdle. The broader biotech sector continues to monitor how effectively emerging delivery mechanisms can target extra-hepatic tissues without causing unintended off-target effects or safety toxicities.
- Undecimal Bio launched with $18 million in venture funding.
- The company emerged from Eleven Therapeutics following a summer spin-out.
- The core scientific objective is delivering siRNA beyond liver tissue.
As the company builds out its pipeline and begins independent research operations, further peer-reviewed preclinical data will be needed to determine whether these delivery approaches can successfully translate from laboratory models into viable human therapies.
Source: Endpoints News
